![Insights from 2024 ASCO® GU Annual Meeting](http://media.vumedi.com/thumbs/channel_logo/2024/1/a56c8c4b-9ce6-43ad-840c-b4fc2e23cbdf.png.200x0_q85.png)
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Insights: "Nivo + Cabozantinib vs. Sunitinib for Previously Untreated Advanced RCC - Results From 55-Month Follow-Up of the CheckMate 9ER Trial"
By
Insights from 2024 ASCO® GU Annual Meeting
FEATURING
Maria Bourlon
By
Insights from 2024 ASCO® GU Annual Meeting
FEATURING
Maria Bourlon
254 views
February 20, 2024
Comments 0
Login to view comments.
Click here to Login
Videos